BCL-2 protein family: attractive targets for cancer therapy
Journal Title
Publication Type
epub ahead of print
Acquired resistance to cell death is a hallmark of cancer. The BCL-2 protein family members play important roles in controlling apoptotic cell death. Abnormal over-expression of pro-survival BCL-2 family members or abnormal reduction of pro-apoptotic BCL-2 family proteins, both resulting in the inhibition of apoptosis, are frequently detected in diverse malignancies. The critical role of the pro-survival and pro-apoptotic BCL-2 family proteins in the regulation of apoptosis makes them attractive targets for the development of agents for the treatment of cancer. This review describes the roles of the various pro-survival and pro-apoptotic members of the BCL-2 protein family in normal development and organismal function and how defects in the control of apoptosis promote the development and therapy resistance of cancer. Finally, we discuss the development of inhibitors of pro-survival BCL-2 proteins, termed BH3-mimetic drugs, as novel agents for cancer therapy.
Apoptosis; BCL-2 protein family; BH3-mimetic drugs; BH3-only proteins; Pro-apoptotic BCL-2 family members; Pro-survival BCL-2 proteins
WEHI Research Division(s)
Blood Cells And Blood Cancer; Blood Cells And Blood Cancer
PubMed ID
Open Access at Publisher's Site
Terms of Use/Rights Notice
Refer to copyright notice on published article.

Creation Date: 2022-11-08 02:27:10
Last Modified: 2022-12-05 07:56:43
An error has occurred. This application may no longer respond until reloaded. Reload 🗙